Paul Dampf, MD
Clinical Cardiac Electrophysiology · Baton Rouge, LANPI 1992996417
Payments from drug & device makers
Across 399 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$2K
- Boston Scientific$853
- Johnson & Johnson$651
- Novartis$564
- Pfizer$442
- plus $3K from 33 others
What the payments were for
- Travel & lodging$3,24326%
- Food & beverage$9,13574%
- Other$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 103 | $5,450 |
| Medtronic(2 entities) | 47 | $1,721 |
| Boston Scientific | 6 | $853 |
| Johnson & Johnson | 43 | $651 |
| Novartis | 32 | $564 |
| Pfizer | 25 | $442 |
| E.r. Squibb & Sons, L.L.C. | 28 | $382 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $343 |
| Amgen | 16 | $252 |
| Kestra Medical Technology Services, Inc. | 8 | $222 |
| Esperion Therapeutics, Inc. | 4 | $161 |
| Irhythm Technologies, Inc. | 7 | $147 |
| Alnylam Pharmaceuticals Inc. | 5 | $128 |
| Abiomed | 1 | $127 |
| Boehringer Ingelheim | 6 | $107 |
| Amarin Pharma, Inc. | 5 | $89 |
| Sanofi-aventis U.S. LLC | 4 | $89 |
| Baxter Healthcare | 3 | $85 |
| AstraZeneca | 6 | $76 |
| Biosense Webster, Inc. | 3 | $71 |
| Merck | 3 | $53 |
| Lundbeck LLC | 3 | $44 |
| Atricure, Inc. | 1 | $33 |
| Cleerly, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Akcea Therapeutics, Inc. | 1 | $24 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Biotronik Inc. | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $20 |
| Convatec Inc. | 1 | $20 |
| Biogen | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Acutus Medical, Inc. | 1 | $13 |
| Sanofi | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,653
- Watchman$760
- Impella$127
- PulseSelect$123
- NA$119
- NEXLIZET$109
- NEXLETOL$109
- Reveal LINQ$101
How this compares
$12,395 in reported general payments places this provider in the 25th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
See all clinical cardiac electrophysiology providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 254 | $284,895 |
| XareltoRivaroxaban | 73 | $80,714 |
| EntrestoSacubitril/Valsartan | 55 | $70,136 |
| JardianceEmpagliflozin | 23 | $29,576 |
| Metoprolol Succinate | 530 | $8,401 |
| Dofetilide | 12 | $4,166 |
| Amiodarone Hcl | 121 | $2,150 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 65 | $1,922 |
| Valsartan | 50 | $1,685 |
| Flecainide Acetate | 44 | $1,544 |
| SotalolSotalol Hcl | 68 | $1,317 |
| Atorvastatin Calcium | 100 | $1,005 |
| Losartan Potassium | 56 | $817 |
| Carvedilol | 42 | $488 |
| Amlodipine Besylate | 60 | $451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $442 | $284,895254 claims |
| Johnson & JohnsonXarelto | $651 | $80,71473 claims |
| NovartisEntresto | $564 | $70,13655 claims |
| Boehringer IngelheimJardiance | $107 | $29,57623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.
Other clinical cardiac electrophysiology in Baton Rouge
- Mark PolletBaton Rouge$90K
- Kenneth CivelloBaton Rouge$69K
- Joshua AymondBaton Rouge$64K
- Henry PatrickBaton Rouge$59K
- Thomas GullattBaton Rouge$31K
- Charles SmithBaton Rouge$29K
- Robert DrennanBaton Rouge$18K
- Wenjie XuBaton Rouge$10K
- Norman DeumiteBaton Rouge$9K
- Nassir MarroucheNew Orleans$11.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.